ArticleFrontiers in neurology2021
Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ultra-High-Field MRI in the Diagnosis and Management of Gliomas: A Systematic Review.Frontiers in neurology · 2022Pooled it
- Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response.Translational psychiatry · 2025Trial
- Article
- Point-of-care mass spectrometry metabolomic analysis enabling intraoperative brain tumor diagnosis.Theranostics · 2025Article
- An Update on MR Spectroscopy in Cancer Management: Advances in Instrumentation, Acquisition, and Analysis.Radiology. Imaging cancer · 2024Review
- Improved Detection of Target Metabolites in Brain Tumors with Intermediate TE, High SNR, and High Bandwidth Spin-Echo Sequence at 5T.AJNR. American journal of neuroradiology · 2024Article
- Single-Voxel MR Spectroscopy of Gliomas with s-LASER at 7T.Diagnostics (Basel, Switzerland) · 2023Article
- Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors.BJR open · 2023Review
- Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.Journal of neuro-oncology · 2022Article
- NMR and Metabolomics-A Roadmap for the Future.Metabolites · 2022Review
- Neuroimaging at 7 Tesla: a pictorial narrative review.Quantitative imaging in medicine and surgery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The onco-metabolite 2-hydroxyglutarate (2HG), a biomarker of IDH-mutant gliomas, can be detected with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.